European consensus‐based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV‐induced dysplasia and field cancerization on behalf of European Association of Dermato‐Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes)

Author:

Kandolf Lidija1ORCID,Peris Ketty23ORCID,Malvehy Josep4,Mosterd Klara56ORCID,Heppt Markus V.78ORCID,Fargnoli Maria Concetta9ORCID,Berking Carola78,Arenberger Petr10ORCID,Bylaite‐Bučinskiene Matilda11,del Marmol Veronique12,Dirschka Thomas1314,Dreno Brigitte15ORCID,Forsea Ana‐Maria16ORCID,Harwood Catherine A.17,Hauschild Axel18,Heerfordt Ida Marie19ORCID,Kauffman Roland20ORCID,Kelleners‐Smeets Nicole56,Lallas Aimilios21ORCID,Lebbe Celeste22,Leiter Ulrike23ORCID,Longo Caterina24ORCID,Mijušković Željko1,Pellacani Giovanni25ORCID,Puig Susana4ORCID,Saiag Philippe26,Šitum Mirna27,Stockfleth Eggert28,Salavastru Carmen29,Stratigos Alexander30,Zalaudek Iris31,Garbe Claus23,

Affiliation:

1. Department of Dermatology, Faculty of Medicine, University of Defence Military Medical Academy Belgrade Serbia

2. UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endrocrino Metaboliche Fondazione Policlinico Universitario A. Gemelli – IRCCS Rome Italy

3. Dermatologia Università Cattolica del Sacro Cuore Rome Italy

4. Dermatology Department of Hospital Clinic of Barcelona, IDIBAPS, CIBER de Enfermedades Raras, Instituto Carlos III University of Barcelona Barcelona Spain

5. Department of Dermatology Maastricht University Medical Centre+ Comprehensive Cancer Centre Maastricht The Netherlands

6. GROW‐School for Oncology and Reproduction Maastricht University Maastricht The Netherlands

7. Department of Dermatology, Uniklinikum Erlangen Friedrich‐Alexander‐University Erlangen‐Nürnberg Erlangen Germany

8. Comprehensive Cancer Center Erlangen‐European Metropolitan Area of Nuremberg (CC ER‐EMN) Erlangen Germany

9. Dermatology, Department of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila Italy

10. Department of Dermatovenereology, Third Faculty of Medicine Charles University and University Hospital of Kralovske Vinohrady Prague Czech Republic

11. Clinic of Infectious Diseases and Dermatovenereology, Centre of Dermatovenereology Vilnius University Vilnius Lithuania

12. Department of Dermatology University Hospital Erasme, Université Libre de Bruxelles Brussels Belgium

13. Faculty of Health University Witten‐Herdecke Witten Germany

14. CentroDerm Clinic Wuppertal Germany

15. Nantes Université, INSERM, CNRS Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001 Nantes France

16. Department of Oncologic Dermatology, Elias University Hospital Bucharest Carol Davila University of Medicine and Pharmacy Bucharest Romania

17. Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry Queen Mary University of London London UK

18. Department of Dermatology University Hospital (UKSH) Kiel Germany

19. Department of Dermatology Copenhagen University Hospital ‐ Bispebjerg and Frederiksberg Copenhagen Denmark

20. Department of Dermatology, Venereology and Allergology Frankfurt University Hospital Frankfurt Germany

21. First Department of Dermatology Aristotle University Thessaloniki Greece

22. Université Paris Cite, AP‐HP Dermato‐oncology Cancer institute APHP, Nord Paris cité, INSERM U976, Saint Louis Hospital Paris France

23. Centre for Dermatooncology, Department of Dermatology Eberhard Karls University Tuebingen Germany

24. Skin Cancer Center Azienda Unità Sanitaria Locale ‐ IRCCS di Reggio Emilia Reggio Emilia Italy

25. Department of Dermatology University of Modena and Reggio Emilia Modena Italy

26. Department of General and Oncologic Dermatology, Ambroise Paré Hospital, APHP, & EA 4340 “Biomarkers in Cancerology and Hemato‐Oncology” UVSQ, Université Paris‐Saclay Boulogne‐Billancourt France

27. Department of Dermatology and Venereology Sestre Milosrdnice University Hospital Center Zagreb Croatia

28. Skin Cancer Center, Department of Dermatology Ruhr‐University Bochum Bochum Germany

29. Department of Pediatric Dermatology, Colentina Clinical Hospital Carol Davila University of Medicine and Pharmacy Bucharest Romania

30. 1st Department of Dermatology‐Venereology National and Kapodistrian University of Athens, Andreas Sygros Hospital Athens Greece

31. Dermatology Clinic, Maggiore Hospital, Department of Medical Sciences University of Trieste Trieste Italy

Abstract

AbstractA collaboration of multidisciplinary experts from the European Association of Dermato‐Oncology, the European Dermatology Forum, the European Academy of Dermatology and Venereology, and the European Union of Medical Specialists was formed to develop European recommendations on AK diagnosis and treatment, based on current literature and expert consensus. This guideline addresses the epidemiology, diagnostics, risk stratification and treatments in immunocompetent as well as immunosuppressed patients. Actinic keratoses (AK) are potential precursors of cutaneous squamous cell carcinoma (cSCC) and display typical histopathologic and immunohistochemical features of this malignancy in an early stage. They can develop into cSSC in situ and become invasive in a low percentage of cases. AK is the most frequent neoplasia in white populations, frequently occurring within a cancerous field induced by ultraviolet radiation. Since it cannot be predicted, which lesion will progress to cSCC and when treatment is usually recommended. The diagnosis of AK and field cancerization is made by clinical examination. Dermatoscopy, confocal microscopy, optical coherence tomography or line‐field confocal‐OCT can help in the differential diagnosis of AK and other skin neoplasms. A biopsy is indicated in clinically and/or dermatoscopically suspicious and/or treatment‐refractory lesions. The choice of treatment depends on patients' and lesion characteristics. For single non‐hyperkeratotic lesions, the treatment can be started upon patient's request with destructive treatments or topical treatments. For multiple lesions, field cancerization treatment is advised with topical treatments and photodynamic therapy. Preventive measures such as sun protection, self‐examination and repeated field cancerization treatments of previously affected skin areas in high‐risk patients are advised.

Publisher

Wiley

Reference161 articles.

1. AGREE II: advancing guideline development, reporting and evaluation in health care

2. HowickJ ChalmersI GlasziouP GreenhalghT HeneghanC LiberatiS et al.The 2011 Oxford CEBM Levels of Evidence (Introductory Document). Oxford Centre for Evidence‐Based Medicine.2011.https://www.cebm.ox.ac.uk/resources/levels‐of‐evidence/ocebm‐levels‐of‐evidence

3. S3 Guideline for actinic keratosis and cutaneous squamous cell carcinoma–short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality‐of‐care indicators;Heppt MV;J Dtsch Dermatol Ges,2020

4. Guidelines of care for the management of actinic keratosis

5. Focused update: Guidelines of care for the management of actinic keratosis

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3